| ELK3 destabilization by speckle-type POZ protein suppresses prostate cancer progression and docetaxel resistance. | ELK3 destabilization by speckle-type POZ protein suppresses prostate cancer progression and docetaxel resistance.
Lee CJ, Lee H, Kim SR, Nam SB, Lee GE, Yang KE, Lee GJ, Chun SH, Kang HC, Lee JY, Lee HS, Cho SJ, Cho YY., Free PMC Article | 05/2/2024 |
| ELK3-ID4 axis governs the metastatic features of triple negative breast cancer. | ELK3-ID4 axis governs the metastatic features of triple negative breast cancer.
Choi JH, Park JD, Choi SH, Ko ES, Jang HJ, Park KS., Free PMC Article | 01/10/2024 |
| ETS transcription factor ELK3 in human cancers: An emerging therapeutic target. | ETS transcription factor ELK3 in human cancers: An emerging therapeutic target.
Al-Hawary SIS, Pallathadka H, Hjazi A, Zhumanov ZE, Alazbjee AAA, Imad S, Alsalamy A, Hussien BM, Jaafer NS, Mahmoudi R. | 08/17/2023 |
| ELK3 Targeting AEG1 Promotes Migration and Invasion of Ovarian Cancer Cells under Hypoxia. | ELK3 Targeting AEG1 Promotes Migration and Invasion of Ovarian Cancer Cells under Hypoxia.
Yu X, Du C, Cui Y, Jiang Y, Feng D. | 07/6/2023 |
| ELK3-CXCL16 axis determines natural killer cell cytotoxicity via the chemotactic activity of CXCL16 in triple negative breast cancer. | ELK3-CXCL16 axis determines natural killer cell cytotoxicity via the chemotactic activity of CXCL16 in triple negative breast cancer.
Jung HY, Lee DK, Lee M, Choi SH, Park JD, Ko ES, Lee J, Park KS, Jung HY., Free PMC Article | 04/1/2023 |
| Deubiquitinase UCHL5 stabilizes ELK3 to potentiate cancer stemness and tumor progression in pancreatic adenocarcinoma (PAAD). | Deubiquitinase UCHL5 stabilizes ELK3 to potentiate cancer stemness and tumor progression in pancreatic adenocarcinoma (PAAD).
Yang Y, Cao L, Guo Z, Gu H, Zhang K, Qiu Z. | 12/3/2022 |
| Circular RNA hsa_circ_0000144 aggravates ovarian Cancer progression by regulating ELK3 via sponging miR-610. | Circular RNA hsa_circ_0000144 aggravates ovarian Cancer progression by regulating ELK3 via sponging miR-610.
Wu D, Liu J, Yu L, Wu S, Qiu X., Free PMC Article | 10/22/2022 |
| Molecular and clinical features of a potential immunotherapy target ELK3 in glioma. | Molecular and clinical features of a potential immunotherapy target ELK3 in glioma.
Xu H, Zhang L, Gao J, Wang J, Wang Y, Xiao D, Chai S., Free PMC Article | 08/13/2022 |
| ELK3 Controls Gastric Cancer Cell Migration and Invasion by Regulating ECM Remodeling-Related Genes. | ELK3 Controls Gastric Cancer Cell Migration and Invasion by Regulating ECM Remodeling-Related Genes.
Lee M, Cho HJ, Park KS, Jung HY., Free PMC Article | 04/23/2022 |
| [Expression characteristics and functional analysis of ELK3 in gastric cancer]. | [Expression characteristics and functional analysis of ELK3 in gastric cancer].
Zhou L, Wu Y, Xin L., Free PMC Article | 10/23/2021 |
| High ELK3 expression is associated with the VEGF-C/VEGFR-3 axis and gastric tumorigenesis and enhances infiltration of M2 macrophages. | High ELK3 expression is associated with the VEGF-C/VEGFR-3 axis and gastric tumorigenesis and enhances infiltration of M2 macrophages.
Dazhi W, Zheng J, Chunling R. | 08/7/2021 |
| LINC00662 promotes cell proliferation, migration and invasion of melanoma by sponging miR-890 to upregulate ELK3. | LINC00662 promotes cell proliferation, migration and invasion of melanoma by sponging miR-890 to upregulate ELK3.
Xia XQ, Lu WL, Ye YY, Chen J. | 05/8/2021 |
| LINC01106 post-transcriptionally regulates ELK3 and HOXD8 to promote bladder cancer progression. | LINC01106 post-transcriptionally regulates ELK3 and HOXD8 to promote bladder cancer progression.
Meng L, Xing Z, Guo Z, Liu Z., Free PMC Article | 04/13/2021 |
| Silencing of ELK3 Induces S-M Phase Arrest and Apoptosis and Upregulates SERPINE1 Expression Reducing Migration in Prostate Cancer Cells. | Silencing of ELK3 Induces S-M Phase Arrest and Apoptosis and Upregulates SERPINE1 Expression Reducing Migration in Prostate Cancer Cells.
Mao Y, Li W, Hua B, Gu X, Pan W, Chen Q, Xu B, Wang Z, Lu C., Free PMC Article | 11/21/2020 |
| ELK3 expressed in lymphatic endothelial cells promotes breast cancer progression and metastasis through exosomal miRNAs. | ELK3 expressed in lymphatic endothelial cells promotes breast cancer progression and metastasis through exosomal miRNAs.
Kim KS, Park JI, Oh N, Cho HJ, Park JH, Park KS., Free PMC Article | 10/24/2020 |
| ELK3 is a novel factor in the ZEB1/E-cadherin axis and ZEB1 has a dual role in ELK3 as a transcriptional activator and as a collaborator to repress E-cadherin expression in triple-negative breast cancer cells. | ZEB1 Collaborates with ELK3 to Repress E-Cadherin Expression in Triple-Negative Breast Cancer Cells.
Cho HJ, Oh N, Park JH, Kim KS, Kim HK, Lee E, Hwang S, Kim SJ, Park KS. | 08/1/2020 |
| In MDA-MB-231 breast cancer cells, knockdown of RSK2 or ELK3 suppressed cell proliferation with accumulation at the G1 cell cycle phase, resulting in inhibition of foci formation and anchorage-independent cancer colony growth in soft agar. | RSK2-Mediated ELK3 Activation Enhances Cell Transformation and Breast Cancer Cell Growth by Regulation of c-fos Promoter Activity.
Yoo SM, Lee CJ, An HJ, Lee JY, Lee HS, Kang HC, Cho SJ, Kim SM, Park J, Kim DJ, Cho YY., Free PMC Article | 08/24/2019 |
| These studies implicate the actin cytoskeleton and ELK3, FLI1, and MKL2 in the transcriptional control of EDNRB and increase our understanding of the plasticity of this receptor | Expression of endothelin type B receptors (EDNRB) on smooth muscle cells is controlled by MKL2, ternary complex factors, and actin dynamics.
Krawczyk KK, Skovsted GF, Perisic L, Dreier R, Berg JO, Hedin U, Rippe C, Swärd K. | 07/13/2019 |
| Study demonstrates that miR-135a regulates cell proliferation in breast cancer by targeting ELK1 and ELK3 oncogenes, and suggests that miR-135a potentially can act as a tumor suppressor. | Tumor-suppressive miRNA-135a inhibits breast cancer cell proliferation by targeting ELK1 and ELK3 oncogenes.
Ahmad A, Zhang W, Wu M, Tan S, Zhu T. | 10/20/2018 |
| Decreased Net expression characterize on-small-cell lung cancer progression. | Increased PEA3/E1AF and decreased Net/Elk-3, both ETS proteins, characterize human NSCLC progression and regulate caveolin-1 transcription in Calu-1 and NCI-H23 NSCLC cell lines.
Sloan KA, Marquez HA, Li J, Cao Y, Hinds A, O'Hara CJ, Kathuria S, Ramirez MI, Williams MC, Kathuria H., Free PMC Article | 05/31/2018 |
| Net might play an important role in pancreatic carcinogenesis | Net expression inhibits the growth of pancreatic ductal adenocarcinoma cell PL45 in vitro and in vivo.
Li B, Wan X, Zhu Q, Li L, Zeng Y, Hu D, Qian Y, Lu L, Wang X, Meng X., Free PMC Article | 05/31/2018 |
| These results suggest that the ELK3-GATA3 axis is a major pathway that promotes metastasis of breast cancer MDA-MB-231 cells | The ELK3-GATA3 axis orchestrates invasion and metastasis of breast cancer cells in vitro and in vivo.
Kong SY, Kim KS, Kim J, Kim MK, Lee KH, Lee JY, Oh N, Park JI, Park JH, Heo SH, Shim SH, Lee DR, Kim KP, Park KS., Free PMC Article | 02/24/2018 |
| The expression levels of Elk-3 in liver cirrhosis tissues were significantly higher than those in chronic hepatitis tissues. | Elk-3 Contributes to the Progression of Liver Fibrosis by Regulating the Epithelial-Mesenchymal Transition.
Li TZ, Kim SM, Hur W, Choi JE, Kim JH, Hong SW, Lee EB, Lee JH, Yoon SK., Free PMC Article | 08/5/2017 |
| We revealed that activation of the PI3K/Akt pathway was the main cause of impaired autophagy in ELK3 KD. Our results suggest that targeting ELK3 may be a potential approach to overcome doxorubicin resistance in breast cancer therapeutics. | PI3K/Akt/mTOR activation by suppression of ELK3 mediates chemosensitivity of MDA-MB-231 cells to doxorubicin by inhibiting autophagy.
Park JH, Kim KP, Ko JJ, Park KS. | 06/24/2017 |
| Taken together, we suggest that ELK3 is an upstream regulator of the NF-kappaB signaling pathway, the inhibition of which leads to the suppression of peritumoral lymphatic vessel development, possibly due to a low VEGFC expression. | The role of ELK3 to regulate peritumoral lymphangiogenesis and VEGF-C production in triple negative breast cancer cells.
Oh N, Park JI, Park JH, Kim KS, Lee DR, Park KS. | 06/10/2017 |